/
EBS
$8.46-$0.07 (-0.82%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$440.1M
52M shares
52-week range
$5.62 – $14.06
34% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Borrow rate
0.32%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-54.53
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $782.4M | $1.11B | $1.58B | $1.77B | $1.12B | $1.05B | $1.04B | $742.9M |
| Cost of revenue | $462.0M | $622.9M | $714.2M | $980.4M | $644.5M | $689.3M | $668.2M | $392.3M |
| Gross profit | $320.4M | $483.1M | $863.1M | $793.2M | $473.0M | $360.0M | $375.4M | $350.6M |
| Gross margin | 41.0% | 43.7% | 54.7% | 44.7% | 42.3% | 34.3% | 36.0% | 47.2% |
| R&D | $142.8M | $226.2M | $237.9M | $235.2M | $188.3M | $111.4M | $70.7M | $53.8M |
| Operating income | $89.8M | $114.1M | $438.5M | $341.4M | −$170.0M | −$726.4M | −$108.7M | $110.2M |
| EBITDA | $155.1M | $258.9M | $609.2M | $504.2M | $15.7M | −$47.0M | $53.4M | $240.4M |
| Net income | $62.7M | $54.5M | $305.8M | $219.5M | −$211.6M | −$760.5M | −$190.6M | $52.6M |
| Net margin | 8.0% | 4.9% | 19.4% | 12.4% | -18.9% | -72.5% | -18.3% | 7.1% |
| EPS (diluted) | 1.22 | 1.04 | 5.67 | 4.06 | -4.22 | -14.85 | -3.60 | 0.93 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $733M | $0.33 | $0.32–$0.33 | 1 |
| 2027 | $892M | $0.91 | $0.91–$0.91 | 1 |
| 2028 | $879M | $0.43 | $0.43–$0.43 | 1 |
| 2029 | $963M | $0.90 | $0.90–$0.90 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$3.14
Price
$8.46
Implied downside
-63%
Peer comparison
Emergent Biosolutions, Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
www.emergentbiosolutions.com- Employees
- 900
- IPO / List date
- Nov 15, 2006
- HQ
- GAITHERSBURG, MD
Held by traders on TradeandTell
No one on the platform currently holds EBS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 656,047 | $5.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded EBS yet.
